Search

Your search keyword '"Leyfman, Yan"' showing total 49 results
Start Over Author "Leyfman, Yan" Publication Year Range Last 10 years
49 results on '"Leyfman, Yan"'

1. Social Media and Professional Development for Oncology Professionals.

Author

Chidharla, Anusha, Utengen, Audun, Drake, Emily, van Londen, G, Subbiah, Ishwaria, Henry, Elizabeth, Murphy, Martina, Barry, Maura, Manochakian, Rami, Moerdler, Scott, Loeb, Stacy, Graff, Stephanie, Leyfman, Yan, Thompson, Michael, Markham, Merry, and Attai, Deanna

Subjects
Delivery of Health Care, Humans, Medical Oncology, Social Media
Abstract

The use of social media continues to increase in health care and academia. Health care practice, particularly the oncologic field, is constantly changing because of new knowledge, evidence-based research, clinical trials, and government policies. Therefore, oncology trainees and professionals continue to strive to stay up-to-date with practice guidelines, research, and skills. Although social media as an educational and professional development tool is no longer completely new to medicine and has been embraced, it is still under-researched in terms of various outcomes. Social media plays several key roles in professional development and academic advancement. We reviewed the literature to evaluate how social media can be used for professional development and academic promotion of oncology professionals.

Published
2022

3. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy.

Author

Huppert, Laura A, Green, Michael D, Kim, Luke, Chow, Christine, Leyfman, Yan, Daud, Adil I, and Lee, James C

Subjects
Humans, Neoplasms, Immunotherapy, Autoimmunity, Immune Tolerance, T-Lymphocytes, Regulatory, Cancer, Metastasis, Organ-specific tolerance, Tissue Tregs, Vaccine Related, Immunization, Inflammatory and immune system, Biochemistry and Cell Biology, Immunology
Abstract

Decades of advancements in immuno-oncology have enabled the development of current immunotherapies, which provide long-term treatment responses in certain metastatic cancer patients. However, cures remain infrequent, and most patients ultimately succumb to treatment-refractory metastatic disease. Recent insights suggest that tumors at certain organ sites exhibit distinctive response patterns to immunotherapy and can even reduce antitumor immunity within anatomically distant tumors, suggesting the activation of tissue-specific immune tolerogenic mechanisms in some cases of therapy resistance. Specialized immune cells known as regulatory T cells (Tregs) are present within all tissues in the body and coordinate the suppression of excessive immune activation to curb autoimmunity and maintain immune homeostasis. Despite the high volume of research on Tregs, the findings have failed to reconcile tissue-specific Treg functions in organs, such as tolerance, tissue repair, and regeneration, with their suppression of local and systemic tumor immunity in the context of immunotherapy resistance. To improve the understanding of how the tissue-specific functions of Tregs impact cancer immunotherapy, we review the specialized role of Tregs in clinically common and challenging organ sites of cancer metastasis, highlight research that describes Treg impacts on tissue-specific and systemic immune regulation in the context of immunotherapy, and summarize ongoing work reporting clinically feasible strategies that combine the specific targeting of Tregs with systemic cancer immunotherapy. Improved knowledge of Tregs in the framework of their tissue-specific biology and clinical sites of organ metastasis will enable more precise targeting of immunotherapy and have profound implications for treating patients with metastatic cancer.

Published
2022

4. Supplement use habits and perceptions in patients with plasma cell disorders.

Author

Leyfman, Yan, primary, Schach, Eliana, additional, Derkach, Andriy, additional, Castro, Francesca, additional, Hurtado Martínez, Jorge Arturo, additional, Sahagun Sanchez Aldana, Ana M., additional, Flores Pérez, Patricia Alejandra, additional, Malik, Maria, additional, Ahlstrom, Jennifer M., additional, Hydren, Jay R, additional, Usmani, Saad Zafar, additional, Mao, Jun J., additional, Chimonas, Susan, additional, and Shah, Urvi A, additional

Published
2024
Full Text
View/download PDF

12. Reimagining Colorectal Cancer Screening: Innovations and Challenges with Dr. Aasma Shaukat.

Author

Cortiana, Viviana, Joshi, Muskan, Chorya, Harshal, Vallabhaneni, Harshitha, Kannan, Shreevikaa, Coloma, Helena S., Park, Chandler H., and Leyfman, Yan

Subjects
FECAL analysis, DNA analysis, HEALTH services accessibility, MEDICAL protocols, DIFFUSION of innovations, IMMUNOCHEMISTRY, DIAGNOSTIC imaging, BLOOD testing, INSURANCE, MEDICAL technology, EARLY detection of cancer, ARTIFICIAL intelligence, MEDICARE, COLORECTAL cancer, GLOBAL burden of disease, AGE distribution, ADENOMA, COMPUTER-aided diagnosis, HEALTH behavior, MACHINE learning, ALGORITHMS, MEDICAL care costs, SENSITIVITY & specificity (Statistics)
Abstract

Simple Summary: Colorectal cancer (CRC) stands as the third most common cancer globally and the second leading cause of cancer-related deaths, imposing a substantial health burden. Recent studies highlight a concerning rise in CRC rates among individuals below 50 years old, prompting the American Cancer Society (ACS) to recommend screening starting at age 45 for average-risk individuals. Dr. Aasma Shaukat's Keynote Conference stresses the urgent need for updated screening strategies to tackle suboptimal adherence rates and effectively manage the increasing burden of CRC. Lowering the adenoma detection screening age could aid in early identification of adenomas in asymptomatic younger patients, potentially reshaping disease epidemiology. Current screening options encompass stool-based tests like multitarget stool DNA (mtDNA) tests, fecal immunochemical testing (FIT), and imaging-based tests. Moreover, blood-based tests are emerging as promising tools for early CRC detection, utilizing innovative techniques and AI algorithms. Medicare mandates specific criteria for national coverage of blood-based tests. Ongoing clinical trials, such as Freenome, Guardant, and CancerSEEK, offer hope for further advancements in blood-based CRC screening. Despite breakthroughs, accessibility and affordability challenges persist. Adapting healthcare systems to accommodate changing CRC epidemiology is imperative. Lowering the screening age and integrating blood-based tests hold the potential to alleviate the CRC-related burden amidst evolving epidemiology. Colorectal cancer (CRC) currently ranks as the third most common cancer and the second leading cause of cancer-related deaths worldwide, posing a significant global health burden to the population. Recent studies have reported the emergence of a new clinical picture of the disease, with a notable increase in CRC rates in younger populations of <50 years of age. The American Cancer Society (ACS) now recommends CRC screening starting at age 45 for average-risk individuals. Dr. Aasma Shaukat's Keynote Conference highlights the critical need for updated screening strategies, with an emphasis on addressing the suboptimal adherence rates and the effective management of the growing burden of CRC. Lowering the adenoma detection screening age can facilitate early identification of adenomas in younger asymptomatic patients, altering the epidemiologic landscape. However, its implications may not be as profound unless a drastic shift in the age distribution of CRC is observed. Currently, various screening options are available in practice, including stool-based tests like multitarget stool DNA (mtDNA) tests, fecal immunochemical testing (FIT), and imaging-based tests. In addition to existing screening methods, blood-based tests are now emerging as promising tools for early CRC detection. These tests leverage innovative techniques along with AI and machine learning algorithms, aiding in tumor detection at a significantly earlier stage, which was not possible before. Medicare mandates specific criteria for national coverage of blood-based tests, including sensitivity ≥ 74%, specificity ≥ 90%, FDA approval, and inclusion in professional society guidelines. Ongoing clinical trials, such as Freenome, Guardant, and CancerSEEK, offer hope for further advancements in blood-based CRC screening. The development of multicancer early detection tests like GRAIL demonstrates a tremendous potential for detecting various solid tumors and hematologic malignancies. Despite these breakthroughs, the question of accessibility and affordability still stands. The ever-evolving landscape of CRC screening reflects the strength of the scientific field in light of an altered disease epidemiology. Lowering screening age along with the integration of blood-based tests with existing screening methods holds great potential in reducing the CRC-related burden. At the same time, it is increasingly important to address the challenges of adaptation of the healthcare system to this change in the epidemiologic paradigm. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Impact of a digital education platform to combat global inequity in oncology education amongst healthcare professionals in lower socioeconomic areas.

Author

Leyfman, Yan, primary, Pawar, Shubhadarshini, additional, Joshi, Muskan, additional, Van de Kieft, Alexandra, additional, Menon, Gayathri P., additional, Wilkerson, William B., additional, Balasubramanian, Maduri, additional, Jackewicz, Sean, additional, Azeez, Ahmed, additional, Chorya, Harshal, additional, Pai, Pallavi, additional, Coloma, Helena S, additional, Wilson, Steven, additional, and Park, Chandler H., additional

Published
2023
Full Text
View/download PDF

27. Soft Tissue Sarcomas

Author

Thornton, Katherine A., primary, Baldini, Elizabeth H., additional, Maki, Robert G., additional, O'Sullivan, Brian, additional, Leyfman, Yan, additional, and Raut, Chandrajit P., additional

Published
2022
Full Text
View/download PDF

28. Immunotherapy in Sarcoma

Author

Moreno Tellez, Cristiam, primary, Leyfman, Yan, additional, D'Angelo, Sandra P., additional, Wilky, Breelyn A., additional, and Dufresne, Armelle, additional

Published
2022
Full Text
View/download PDF

38. The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper

Author

Stawicki, StanislawP, primary, Jeanmonod, Rebecca, additional, Miller, AndrewC, additional, Paladino, Lorenzo, additional, Gaieski, DavidF, additional, Yaffee, AnnaQ, additional, De Wulf, Annelies, additional, Grover, Joydeep, additional, Papadimos, ThomasJ, additional, Bloem, Christina, additional, Galwankar, SagarC, additional, Chauhan, Vivek, additional, Firstenberg, MichaelS, additional, Di Somma, Salvatore, additional, Jeanmonod, Donald, additional, Garg, SonaM, additional, Tucci, Veronica, additional, Anderson, HarryL, additional, Fatimah, Lateef, additional, Worlton, TamaraJ, additional, Dubhashi, SiddharthP, additional, Glaze, KrystalS, additional, Sinha, Sagar, additional, Opara, IjeomaNnodim, additional, Yellapu, Vikas, additional, Kelkar, Dhanashree, additional, El-Menyar, Ayman, additional, Krishnan, Vimal, additional, Venkataramanaiah, S, additional, Leyfman, Yan, additional, Saoud Al Thani, HassanAli, additional, B Nanayakkara, PrabathW, additional, Nanda, Sudip, additional, Cioè-Peña, Eric, additional, Sardesai, Indrani, additional, Chandra, Shruti, additional, Munasinghe, Aruna, additional, Dutta, Vibha, additional, Dal Ponte, SilvanaTeixeira, additional, Izurieta, Ricardo, additional, Asensio, JuanA, additional, and Garg, Manish, additional

Published
2020
Full Text
View/download PDF

39. Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)

Author

Leyfman, Yan, primary, Joffe, Erel, additional, Drill, Esther, additional, Rajeeve, Sridevi, additional, Zelenetz, Andrew D., additional, Palomba, Maria Lia Lia, additional, Moskowitz, Craig H., additional, Portlock, Carol S., additional, Noy, Ariela, additional, Horwitz, Steven M., additional, Moskowitz, Alison J., additional, Hamlin, Paul A., additional, Matasar, Matthew J, additional, Kumar, Anita, additional, von Keudell, Gottfried R., additional, Batlevi, Connie Lee, additional, Younes, Anas, additional, and Straus, David J., additional

Published
2019
Full Text
View/download PDF

43. The Impact of a Virtual Platform to Reduce Hematology-Oncology Educational Disparities Amongst Healthcare Professionals in Lower Socioeconomic Regions Globally

Author

Leyfman, Yan, Menon, Gayathri P., Joshi, Muskan, Balasubramanian, Maduri, Smith, Keira P., Heller, Elizabeth J., Coloma, Helena S., Van de Kieft, Alexandra, Hashim, Ahmed, Chorya, Harshal, Abbas, Rabab H., Alves, Gabriele, Ghazal, Jenna, Wilson, Steven, Grivna, Shane, and Park, Chandler Howard

Abstract

Introduction:

Published
2023
Full Text
View/download PDF

44. Exosomal Vesicles: A Therapeutic Strategy Against Severe Sars-Cov-2 in Multiple Myeloma Patients

Author

Leyfman, Yan, Joshi, Muskan, Menon, Gayathri P., Van de Kieft, Alexandra, and Park, Chandler Howard

Abstract

During the early phase of the pandemic, studies revealed that COVID-19 patients with multiple myeloma (MM) had significantly higher hospitalization rates (56%), with 20% requiring critical care and 18% facing an increased risk of mortality. MM patients undergoing anticancer therapy showed a 55% higher risk of mortality when infected with COVID-19. Even in the post-pandemic world, MM patients remain at heightened risk for breakthrough infections and severe SARS-CoV-2 due to their immunocompromised status, necessitating hospitalization. While both active and remission MM patients exhibited worse outcomes than COVID-19 patients without cancer, limited research exists to elucidate the underlying causes. In this study, we aimed to (1) develop a model elucidating the pathogenesis and interplay between MM and severe SARS-CoV-2, and (2) explain the efficacy and therapeutic potential of Exosomal Vesicles (EVs) as an intervention against severe SARS-CoV-2, supported by clinical evidence.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results